Why Big Pharma Is Pivoting To ‘Guided Missile’ Drugs

After the last three years, the pharmaceutical industry has been irreparably damaged—by its own doing.

The pushing of the experimental Covid-19 shots has permanently tarnished the reputation of an industry that was already losing consumer confidence prior to the plandemic.

At roughly the same time, the advancement of Medicare is putting a damper on some of the pharmaceutical industry’s most profitable flagship drugs.

Because of this, the pharmaceutical industry is increasingly looking to build portfolios of ‘medium-cap’ drugs not targeted by the government’s Medicare policies.

Some of these drugs include ‘guided missile’ drugs known as ADCs. An ADC is a combination of antibodies and toxins that purportedly target cancer with precision.

Several users on X provided data and studies surrounding ADCs and their proposed uses:

In light of $AZN ESMO call yesterday, here's a paper from February on ADC combos

Antibody–drug conjugates: in search of partners of choice: Trends in Cancer https://t.co/WsbKfk31gX pic.twitter.com/lW59PxqowQ

— Bertrand Delsuc (@BertrandBio) October 24, 2023

At #ESMO23 navigating all the new #ADC data?

Must read papers:

ADC dogma: https://t.co/qqKv0JgD4b

ADC toxicity: https://t.co/1z7sg41cpp

ADC clinical development: https://t.co/xgmVjfBQmv

ADC targets: https://t.co/EaECF4APGb

ADC payload exposure: https://t.co/GgnQlWMkdH

— Raffaele Colombo (@raffcolo) October 21, 2023

Dr. Giampaolo Bianchini's @BianchiniGP discussion on ADC drug development is highly insightful, and it's not limited solely to HS-20089. pic.twitter.com/eUlbon5V11

— Byung-June Park (@onco_park) October 26, 2023

The Wall Street Journal had more on the story:

Earlier this month, Merck and Daiichi Sankyo agreed to jointly develop and commercialize three potential ADCs in a deal worth up to $22 billion.

That came after Merck was unable to come to an agreement to acquire Seagen, another ADC company that was later snagged by rival Pfizer PFE 1.33%increase; green up pointing triangle for $43 billion.

Dr. Nancy Lin presented even more data and stated: “More data of a class effect of ADC in the CNS. Great to see pts with brain mets included earlier in drug development. We should be doing this across the board for ADCs. Our pts deserve our collective advocacy on this issue.”

More data of a class effect of ADC in the CNS. Great to see pts with brain mets included earlier in drug development. We should be doing this across the board for ADCs. Our pts deserve our collective advocacy on this issue. https://t.co/wBHuZ4Fvmr

— Nancy Lin, MD (@nlinmd) October 22, 2023

Previously, Reuters reported:

Dozens of drugmakers are conducting human trials for a record 89 therapies that pair antibodies with toxic agents to fight cancer, evidence of renewed confidence in an approach that has long fallen short of its promise, an analysis compiled for Reuters shows.